Author

Jakob Sauer

Medical University of Vienna

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 1 Assay:electrophysiology· 1 Approach:experimental assay· 1 Organism:mouse· 1 Organism:rat· 1

Frequent Co-Authors

Anna Stary‐WeinzingeriD· 1 shared Attila KissiD· 1 shared Bruno Karl PodesseriD· 1 shared Christopher DostaliD· 1 shared Hannes TodtiD· 1 shared Helmut KubistaiD· 1 shared Isabella SalzeriD· 1 shared Jessica MarksteineriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Anna Stary‐WeinzingerORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The sodium/glucose cotransporter 2 inhibitor empagliflozin is a pharmacological chaperone of cardiac Nav1.5 channels

Jakob Sauer, Jessica Marksteiner, Martin HOHENEGGER, Hannes Todt, Helmut Kubista, Christopher Dostal, Attila Kiss, Bruno Karl Podesser, Isabella Salzer, Xaver Koenig, Anna Stary‐Weinzinger, Karlheinz Hilber, Oliver Kudlacek

This study shows empagliflozin enhances peak sodium current in Nav1.5 channels by acting as a pharmacological chaperone, potentially reducing arrhythmia risk in Duchenne muscular dystrophy.

American Journal of Physiology-Heart and Circulatory Physiology · Aug 13, 2025Peer-reviewedPharmacology & Toxicology